• Explore /
  • Poster
  • / A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination (HR) defective or loss of heterozygosity (LOH) high-metastatic esophageal/GEJ/proximal gastric adenocarcinoma: A Big Ten Cancer Research Consortium study.

A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination (HR) defective or loss of heterozygosity (LOH) high-metastatic esophageal/GEJ/proximal gastric adenocarcinoma: A Big Ten Cancer Research Consortium study.

Abstract Poster

Authors

Hirva Mamdani

Hirva Mamdani

Karmanos Cancer Institute, Detroit, MI

Hirva Mamdani , Rutika Mehta , Christos Fountzilas , Milan Radovich , Susan Perkins , Shadia Ibrahim Jalal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03840967

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr TPS472)

Abstract #

TPS472

Poster Bd #

L16

Abstract Disclosures

Similar Posters

First Author: Jonathan Poh

First Author: Anup Kasi

First Author: Qiuxiang Ou

First Author: Severine Guiu Lahaye